These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 535136)

  • 1. The disposition of cyclophosphamide in a group of myeloma patients.
    Bramwell V; Calvert RT; Edwards G; Scarffe H; Crowther D
    Cancer Chemother Pharmacol; 1979; 3(4):253-9. PubMed ID: 535136
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Repeated investigations of cyclophosphamide disposition in myeloma patients receiving intermittent chemotherapy.
    Edwards G; Calvert RT; Crowther D; Bramwell V; Scarffe H
    Br J Clin Pharmacol; 1980 Sep; 10(3):281-5. PubMed ID: 7437246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of renal insufficiency on the pharmacokinetics of cyclophosphamide and some of its metabolites.
    Juma FD; Rogers HJ; Trounce JR
    Eur J Clin Pharmacol; 1981; 19(6):443-51. PubMed ID: 7250178
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of cyclophosphamide and alkylating activity in man after intravenous and oral administration.
    Juma FD; Rogers HJ; Trounce JR
    Br J Clin Pharmacol; 1979 Sep; 8(3):209-17. PubMed ID: 497087
    [No Abstract]   [Full Text] [Related]  

  • 5. Cross-resistance to alkylating agents in multiple myeloma.
    Bladé J; Feliú E; Rozman C; Estapé J; Millá A; Montserrat E
    Cancer; 1983 Sep; 52(5):786-9. PubMed ID: 6871821
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The influence of interferon-alpha on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite in patients with multiple myeloma.
    Hassan M; Nilsson C; Olsson H; Lundin J; Osterborg A
    Eur J Haematol; 1999 Sep; 63(3):163-70. PubMed ID: 10485271
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of valproic acid on pharmacokinetics of active metabolites of cyclophosphamide in mice.
    Goto M; Ohnishi C; Yamashina H; Johno I; Kitazawa S
    J Pharmacobiodyn; 1987 Jan; 10(1):8-14. PubMed ID: 3108487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effect of damaged liver parenchyma, renal insufficiency and hemodialysis on the pharmacokinetics of cyclophosphamide and its activated metabolites].
    Wagner T; Heydrich D; Bartels H; Hohorst HJ
    Arzneimittelforschung; 1980; 30(9):1588-92. PubMed ID: 7193030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alkylating agents as leukemogens in multiple myeloma.
    Karchmer RK; Amare M; Larsen WE; Mallouk AG; Caldwell GG
    Cancer; 1974 Apr; 33(4):1103-7. PubMed ID: 4522494
    [No Abstract]   [Full Text] [Related]  

  • 10. Myopericarditis caused by cyclophosphamide used to mobilize peripheral blood stem cells in a myeloma patient with renal failure.
    Yamamoto R; Kanda Y; Matsuyama T; Oshima K; Nannya Y; Suguro M; Chizuka A; Hamaki T; Takezako N; Miwa A; Kami M; Mori S; Kojima T; Saito K; Itaoka Y; Kashida M
    Bone Marrow Transplant; 2000 Sep; 26(6):685-8. PubMed ID: 11041571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biliary elimination of cyclophosphamide in man.
    Dooley JS; James CA; Rogers HJ; Stuart-Harris R
    Cancer Chemother Pharmacol; 1982; 9(1):26-9. PubMed ID: 7139850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adriamycin (NSC-123127) in the treatment of alkylator-resistant multiple myeloma: a pilot study.
    Alberts DS; Salmon SE
    Cancer Chemother Rep; 1975; 59(2 Pt 1):345-50. PubMed ID: 1097093
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of cyclophosphamide on the pharmacokinetics of triiodothyronine in the male rat.
    Angley MT; Sansom LN; Smeaton TC; Stupans I
    J Pharm Pharmacol; 1996 Apr; 48(4):386-9. PubMed ID: 8794988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of plasma cell myeloma with cytotoxic agents.
    Bergsagel DE; Pruzanski W
    Arch Intern Med; 1975 Jan; 135(1):172-6. PubMed ID: 803363
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interaction of cimetidine but not ranitidine with cyclophosphamide in mice.
    Dorr RT; Soble MJ; Alberts DS
    Cancer Res; 1986 Apr; 46(4 Pt 1):1795-9. PubMed ID: 3948164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The treatment of multiple myeloma].
    Pick AI; Schoenfeld
    Harefuah; 1974 Jun; 86(11):558-60. PubMed ID: 4849963
    [No Abstract]   [Full Text] [Related]  

  • 17. Drug - resistant multiple myeloma. A trial with the M 2 cyclic alkylating agent polychemotherapy.
    Buonanno G; Tortarolo M; Valente A; Castaldo C; Russolillo S; Gonnella F
    Haematologica; 1978 Feb; 63(1):45-55. PubMed ID: 417971
    [No Abstract]   [Full Text] [Related]  

  • 18. Effective treatment of advanced multiple myeloma refractory to alkylating agents.
    Barlogie B; Smith L; Alexanian R
    N Engl J Med; 1984 May; 310(21):1353-6. PubMed ID: 6546971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modification of the alkylating ability of cyclophosphamide by fresh plasma.
    Hill BT; Harrap KR
    Chem Biol Interact; 1972 Jul; 5(2):117-25. PubMed ID: 5064934
    [No Abstract]   [Full Text] [Related]  

  • 20. Factors responsible for bone marrow toxicity after treatment of myeloma patients with different alkylating agents.
    Ringborg U; Lewensohn R
    Acta Med Scand; 1978; 203(4):276-8. PubMed ID: 645439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.